Maravai LifeSciences (MRVI) Scheduled to Post Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) will be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The business had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Stock Up 0.4 %

MRVI stock opened at $9.01 on Tuesday. Maravai LifeSciences has a 1-year low of $4.52 and a 1-year high of $16.62. The business has a fifty day moving average price of $8.04 and a 200-day moving average price of $6.69. The company has a debt-to-equity ratio of 0.70, a current ratio of 8.00 and a quick ratio of 7.41. The stock has a market capitalization of $2.27 billion, a P/E ratio of -10.01 and a beta of 0.03.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on MRVI shares. Royal Bank of Canada boosted their price target on Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Stifel Nicolaus decreased their price target on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Finally, Craig Hallum assumed coverage on Maravai LifeSciences in a research report on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and a consensus target price of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.